Phone Screenings Open and Site Initiation Visits Conducted at Study Sites for Expanded Access Program for MDMA-Assisted Therapy for PTSD
January 24, 2022
On December 10, 2021, our multi-site expanded access study site for MDMA-assisted therapy for patients with treatment-resistant PTSD at the Pearl Psychedelic Institute in Waynesville, North Carolina, was …
Psyche Unbound, a collection of essays in honor of Stanislav Grof, to be released in January 2022
December 8, 2021
Psyche Unbound: Essays in Honor of Stanislav Grof is an extraordinary compilation of twenty-two essays that honor the path-breaking lifework of Stanislav Grof, M.D., Ph.D., the world’s leading researcher …
MAPS and Vine Ventures Pioneer Novel Regenerative Funding Structure to Infuse Psychedelic-Assisted Therapy Research and Access With Timely $70 Million
December 2, 2021
Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once …
Publication of MAPP1 Results in Nature Medicine: A Message from Amy Emerson, MAPS PBC CEO
May 11, 2021
We’ve finally reached the point where we can shout our good news from the roof tops and publicly celebrate the work of this amazing team! The publication of our MAPP1 findings is official as of this …
MDMA-Assisted Therapy for PTSD in couples may reduce PTSD symptoms and improve couples’ happiness
December 8, 2020
A Phase 1/2 open-label treatment development study of MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in dyads in which one member has chronic posttraumatic stress disorder (PTSD) shows MDMA-Assisted …
Startle Testing with MDMA: Thirty-Fourth Participant Receives Experimental Treatment, Database Locked
August 2, 2020
On August 1, 2020, the thirty-fourth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
Startle Testing with MDMA: Thirty-First Participant Receives Experimental Treatment
March 25, 2020
On March 25, 2020, the thirty-first participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
Startle Testing with MDMA: Twenty-Eighth Participant Receives Experimental Treatment
February 21, 2020
On February 19, 2020, the twenty-eighth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
Startle Testing with MDMA: Twenty-Ninth Participant Receives Experimental Treatment
February 21, 2020
On March 11, 2020, the twenty-ninth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
Startle Testing with MDMA: Recruiting Volunteers
January 24, 2020
Our ongoing study of the effect of MDMA on startle testing is recruiting healthy volunteers. Led by Principal Investigator Barbara Rothbaum, Ph.D., this study is conducted at Emory University in Atlanta, …
FDA Lifts Clinical Hold for Expanded Access Program Protocol
December 19, 2019
On December 20, 2019, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on MAPS’ proposed Expanded Access protocol for MDMA-assisted psychotherapy for posttraumatic stress disorder …
Startle Testing with MDMA: Twenty-Fourth Participant Receives Experimental Treatment
December 18, 2019
On December 18, 2019, the twenty-fourth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …